Fibrocytes mediate intimal hyperplasia post-vascular injury and are regulated by two tissue factor-dependent mechanisms

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 5, 2013, Pages 963-974

  Chen, D ^a   Ma, L ^a   Tham, E L ^a   Maresh, S ^a   Lechler, R I ^a   Mcvey, J H ^a   Dorling, A ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Blood coagulation; Neointima; Thrombin; Thromboplastin; Vascular system injuries

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CD11B ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 1; FIBRONECTIN; HYBRID PROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; THROMBOPLASTIN; THY 1 ANTIGEN; TISSUE FACTOR PATHWAY INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CD34 SELECTION; CELL COUNT; CELL HYPERPLASIA; CELL SUBPOPULATION; CELLS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FIBROCYTE; HOMEOSTASIS; IMMUNOFLUORESCENCE; MOLECULAR MECHANICS; MOUSE; NEOINTIMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE REPAIR;

ANIMALS; FIBROBLASTS; HYPERPLASIA; IMMUNOPHENOTYPING; MICE; REAL-TIME POLYMERASE CHAIN REACTION; THROMBOPLASTIN; TUNICA INTIMA;

EID: 84877908375     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12198     Document Type: Article

References (31)

1. Huynh TT, Davies MG, Thompson MA, Ezekowitz MD, Hagen P, Annex BH. Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimal hyperplasia in experimental vein grafts. J Vasc Surg 2001; 33: 400-7.
2. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med 1996; 2: 293-8.
3. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
4. Ma L, Dorling A. The roles of thrombin and protease-activated receptors in inflammation. Semin Immunopathol 2012; 34: 63-72.
5. Carmeliet P. Biomedicine. Clotting factors build blood vessels. Science 2001; 293: 1602-4.
6. Shimizu K, Sugiyama S, Aikawa M, Fukumoto Y, Rabkin E, Libby P, Mitchell RN. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med 2001; 7: 738-41.
7. Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV, Russell SJ, Litzow MR, Edwards WD. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci USA 2003; 100: 4754-9.
8. Iwata H, Manabe I, Fujiu K, Yamamoto T, Takeda N, Eguchi K, Furuya A, Kuro-o M, Sata M, Nagai R. Bone marrow-derived cells contribute to vascular inflammation but do not differentiate into smooth muscle cell lineages. Circulation 2010; 122: 2048-57.
9. + bone marrow-derived progenitor cells expressing membrane-tethered anticoagulant fusion proteins. J Thromb Haemost 2006; 4: 2191-8.
10. + vascular progenitors. Blood 2008; 111: 4155-64.
11. Chen D, Shrivastava S, Ma L, el Tham L, Abrahams J, Coe JD, Scott D, Lechler RI, McVey JH, Dorling A. Inhibition of thrombin receptor signaling on alpha-smooth muscle actin(+) CD34(+) progenitors leads to repair after murine immune vascular injury. Arterioscler Thromb Vasc Biol 2012; 32: 42-9.
12. Coffelt SB, Lewis CE, Naldini L, Brown JM, Ferrara N, De Palma M. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol 2010; 176: 1564-76.
13. Delacroix S, Simari RD. Tissue factor-thrombin-PAR-1 pathway: a novel link between bone marrow and blood vessel. Arterioscler Thromb Vasc Biol 2012; 32: 3-4.
14. Chen D, Giannopoulos K, Shiels PG, Webster Z, McVey JH, Kemball-Cook G, Tuddenham E, Moore M, Lechler R, Dorling A. Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium. Blood 2004; 104: 1344-9.
15. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516-9.
16. Chen DX, Weber M, McVey JH, Kemball-Cook G, Tuddenham EGD, Lechler RI, Dorling A. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4: 1958-63.
17. Chen D, Carpenter A, Abrahams J, Chambers RC, Lechler RI, McVey JH, Dorling A. Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med 2008; 205: 1739-46.
18. Chen D, Riesbeck K, McVey JH, Kemball-Cook G, Tuddenham EG, Lechler RI, Dorling A. Regulated inhibition of coagulation by porcine endothelial cells expressing P-selectin-tagged hirudin and TFPI fusion proteins. Transplantation 1999; 68: 832-9.
19. Riesbeck K, Chen D, Kemball-Cook G, McVey JH, George AJ, Tuddenham EG, Dorling A, Lechler RI. Expression of hirudin fusion proteins in mammalian cells: a strategy for prevention of intravascular thrombosis. Circulation 1998; 98: 2744-52.
20. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res 1993; 73: 792-6.
21. Pilling D, Fan T, Huang D, Kaul B, Gomer RH. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE 2009; 4: e7475.
22. Reilkoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol 2011; 11: 427-35.
23. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1: 71-81.
24. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001; 166: 7556-62.
25. Varcoe RL, Mikhail M, Guiffre AK, Pennings G, Vicaretti M, Hawthorne WJ, Fletcher JP, Medbury HJ. The role of the fibrocyte in intimal hyperplasia. J Thromb Haemost 2006; 4: 1125-33.
26. Onuta G, van Ark J, Rienstra H, Boer MW, Klatter FA, Bruggeman CA, Zeebregts CJ, Rozing J, Hillebrands JL. Development of transplant vasculopathy in aortic allografts correlates with neointimal smooth muscle cell proliferative capacity and fibrocyte frequency. Atherosclerosis 2010; 209: 393-402.
27. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Mopps B, Mericskay M, Gierschik P, Biessen EA, Weber C. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res 2005; 96: 784-91.
28. Tallone T, Realini C, Bohmler A, Kornfeld C, Vassalli G, Moccetti T, Bardelli S, Soldati G. Adult human adipose tissue contains several types of multipotent cells. J Cardiovasc Transl Res 2011; 4: 200-10.
29. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011; 21: 193-215.
30. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97.
31. Dulauroy S, Di Carlo SE, Langa F, Eberl G, Peduto L. Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med 2012; 18: 1262-70.